Abstract: SA-PO0780
Methods of a Pilot Clinical Trial: Transcutaneous Vagus Nerve Stimulation for the Treatment of Childhood Nephrotic Syndrome
Session Information
- Glomerular Research: Design, Registries, Surveys, and Epidemiology
November 08, 2025 | Location: Exhibit Hall, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Glomerular Diseases
- 1402 Glomerular Diseases: Clinical, Outcomes, and Therapeutics
Authors
- Sethna, Christine B., Northwell Health, New Hyde Park, New York, United States
- Karan, Meghana, Northwell Health, New Hyde Park, New York, United States
- Abdullah, Mahie M., Northwell Health, New Hyde Park, New York, United States
- Schuchman, Matthew, Northwell Health, New Hyde Park, New York, United States
- Vento, Suzanne, Northwell Health, New Hyde Park, New York, United States
- Meyers, Kevin E.C., The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
Background
Children with nephrotic syndrome are exposed to prolonged courses of steroids and other immunosuppressant medications with adverse side effect profiles and variable efficacy. There is an urgent need to identify novel and safe therapies to treat nephrotic syndrome in children. Stimulation of the vagus nerve, which can be activated non-invasively by transcutaneous auricular vagus nerve stimulation (taVNS), modulates the immune system by the inflammatory reflex and spleen. The central hypothesis is that activation of the inflammatory reflex via taVNS modulates the immune response, attenuates relapses and proteinuria, and reduces reliance on immunosuppressant medications in children with nephrotic syndrome. The objective is to conduct pilot clinical trials to evaluate the feasibility and tolerability of taVNS for the treatment of nephrotic syndrome in children and generate preliminary data to guide power calculations for a future larger study.
Methods
This NIH-funded pilot study will enroll 30 children with FRNS and 10 children with SRNS age 3-17 years from two sites in two parallel, double-blinded, randomized placebo-controlled trials comparing taVNS use for 10 minutes twice a day with sham therapy for 26 weeks. To test for feasibility and tolerability of the clinical trial, the process of recruitment, adherence, device functionality, time and resource utilization, and safety monitoring will be examined. Preliminary data gathered from this pilot study will then be used to determine whether a subsequent larger main trial should move forward. Further, immune markers including serum and monocyte-stimulated cytokines and anti-nephrin antibodies will be measured in order to characterize the immunomodulatory effect of taVNS therapy.
Results
The study is currently enrolling participants.
Conclusion
Accomplishing the goals of this pilot study will provide preliminary data that will inform the design of and strengthen the implementation of a planned larger clinical trial. Providing these preliminary data that are essential to conduct a large-scale trial will address a significant knowledge gap and will pave the way for evaluation of an innovative, non-pharmacologic, non-invasive, steroid-sparing approach to the treatment of idiopathic nephrotic syndrome in children.
Funding
- NIDDK Support